Clinical Trial Update: Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the termination of a Phase 1/2 study evaluating bevacizumab with or without MEDI-522 in patients with unresectable or metasta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• MEDI-522

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Renal Cell Cancer, Renal Cell Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2014-01-14